Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Allogenic Stem Cells in Anal Fistulas of Crohn's Disease: From Promising Premises to Real Life Experience
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38862158
BACKGROUND: Allogenic adipocyte stem cells represent an unprecedented opportunity for regenerative therapy to treat Crohn anal fistulas. Apart from the results of one 8-year-old trial, scientific evidence remains scarce. METHODS: Data from consecutive patients treated with darvadstrocel for Crohn anal fistulas were reviewed at 6 first tertiary reference centers. The …
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38862178 DOI: 10.1093/ibd/izae131
The past decade has seen a substantial increase in the number of randomized controlled trials (RCTs) conducted in inflammatory bowel disease (IBD). Randomized controlled trials are the gold standard method for generating robust evidence of drug safety and efficacy but are expensive, time-consuming, and may have ethical implications. Observational studies …
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38661492
BACKGROUND: Regulatory guidance for Crohn's disease trials recommends coprimary efficacy end points that evaluate both symptoms and mucosal inflammation. We aimed to characterize the operating properties of commonly used disease activity assessments alone and in combination. METHODS: Endoscopic and clinical data were available for 129 participants from the Study of …
Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38666643 DOI: 10.1093/ibd/izae095
BACKGROUND: Data on variation in outcomes and costs of the treatment of inflammatory bowel disease (IBD) can be used to identify areas for cost and quality improvement. It can also help healthcare providers learn from each other and strive for equity in care. We aimed to assess the variation in …
Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38676392
BACKGROUND: An increasing incidence of pediatric-onset inflammatory bowel disease (PIBD) has been reported in many countries. However, the global burden and distribution of this disease remain less understood. We aimed to examine the global epidemiology and trends of PIBD from 1990 to 2019. METHODS: Data from the 2019 Global Burden …
Tolerogenic dendritic cell-mediated regulatory T cell differentiation by Chinese herbal formulation attenuates colitis progression
Publication Year: 2025 Source: J Adv Res PMID: 38677546
No Abstract
T3-T4 index as a prognostic marker of response to biological treatments in elderly patients with inflammatory bowel disease
Publication Year: 2025 Source: Rev Esp Enferm Dig PMID: 38685905
Following the growing trend of trying to individualise treatment in inflammatory bowel disease and in view of the challenge posed by elderly patients requiring biologic treatments, we have conducted a study in our centre to assess the T3/T4 index as a predictor of response to biologic treatments in elderly patients.
Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38701328 DOI: 10.1093/ibd/izae087
BACKGROUND: The incidence of pediatric inflammatory bowel disease (IBD) is rising, and there is an increasing need to support adolescents when they transition to adult care. Evidence supports the use of a structured transition process but there is great variation across Australasia. The study aim was to develop evidence and …
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 38704439
BACKGROUND: Janus kinase (JAK) inhibitors tofacitinib and upadacitinib are effective therapies for inflammatory bowel disease and rheumatologic disorders but currently possess a warning for increased venous thromboembolism (VTE) risk. Some patients with a history of VTE may benefit from a JAK inhibitor, but the risk of recurrent VTE with JAK …
Targeting programmed cell death in inflammatory bowel disease through natural products: New insights from molecular mechanisms to targeted therapies
Publication Year: 2025 Source: Phytother Res PMID: 38706097 DOI: 10.1002/ptr.8216
Inflammatory bowel disease (IBD) is an autoimmune disorder primarily characterized by intestinal inflammation and recurrent ulceration, leading to a compromised intestinal barrier and inflammatory infiltration. This disorder's pathogenesis is mainly attributed to extensive damage or death of intestinal epithelial cells, along with abnormal activation or impaired death regulation of immune …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide